IRAP Protein Detection Using Monoclonal Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assaying the extracellular domain of IRAP protein in biological media are non-specific and unreliable, particularly in diagnosing and monitoring pathologies related to IRAP concentration changes, such as preeclampsia and premature labor, due to the use of enzymatic assays with non-specific substrates.
Innovation Solution
Development of a specific in vitro method using monoclonal antibodies that target the extracellular domain of IRAP protein, allowing for precise measurement of its concentration in serum, plasma, or tissues, and inhibition of its enzymatic activity for therapeutic purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If enzymatic assays with non-specific substrates are used to assay IRAP protein, then the assay can be performed, but the measurement precision and reliability are poor due to non-specific recognition of other aminopeptidases
Solution Approach 1:
The patent introduces a specific substrate (peptide with sequence Pro-Ala-Pro-Val-Leu) as an intermediary that specifically binds to IRAP enzyme active site. This substrate acts as a mediator between the enzyme and detection system, enabling selective measurement of IRAP activity without cross-reactivity with other aminopeptidases, thereby resolving the specificity problem while maintaining assay simplicity
Solution Approach 2:
The patent changes the chemical parameters of the assay substrate from non-specific synthetic substrates to a specifically designed peptide sequence (Pro-Ala-Pro-Val-Leu) that matches IRAP's substrate specificity. This parameter change in substrate structure enables selective recognition and hydrolysis by IRAP, improving measurement precision without complicating the assay procedure
2Reliability
If polyclonal antibodies raised against whole P-LAP protein are used, then the antibody can be obtained, but the antibody specificity is low and cross-reactivity with other aminopeptidases occurs
Solution Approach 1:
The patent segments the P-LAP protein into its extracellular domain (amino acids 1-738) and uses this specific segment for immunization. By focusing on a discrete functional domain rather than the whole protein, the resulting antibodies achieve high specificity for IRAP while maintaining ease of production through standard hybridoma techniques
Solution Approach 2:
The patent applies local quality by directing the immune response to a specific region (extracellular domain) of the IRAP protein that contains unique epitopes. This localized immunization strategy ensures antibodies recognize only IRAP and not other aminopeptidases, improving diagnostic reliability without significantly complicating the antibody manufacturing process
3Reliability
If non-specific substrates are used in enzymatic assays, then the assay can be performed, but the reliability of diagnosis and monitoring of IRAP-related pathologies is compromised
Solution Approach 1:
The patent introduces a specifically designed peptide substrate (Pro-Ala-Pro-Val-Leu) as an intermediary that mediates selective interaction with IRAP. This substrate acts as a molecular key that fits only the IRAP lock, enabling reliable detection and monitoring of IRAP levels in physiological and pathological conditions without interference from other enzymes
Solution Approach 2:
The patent changes the substrate parameter from generic synthetic substrates to a specifically sequenced peptide (Pro-Ala-Pro-Val-Leu) that reflects IRAP's natural substrate preferences. This parameter optimization ensures high-affinity binding and hydrolysis only by IRAP, thereby guaranteeing diagnosis reliability for IRAP-related pathologies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables reliable and specific diagnosis and monitoring of IRAP-related pathologies, including insulin resistance, diabetes, and cancer, by accurately assessing IRAP protein levels and activity, thereby guiding treatment efficacy and resistance to chemotherapy.
Implementation Method 1
Development of a specific in vitro method using monoclonal antibodies that target the extracellular domain of IRAP protein, allowing for precise measurement of its concentration in serum, plasma, or tissues
Implementation Method 2
This enzyme degrades oxytocin, vasopressin, angiotensin II and III as well as a series of other peptides
Data Source
AI summary
The use of the IRAP protein for implementing methods of diagnosis and of prognosis.